Letter to the editor in response to the article "COVID-19 and diabetes: Can DPP4 inhibition play a role?".
作者信息
Kokic Males Visnja
机构信息
Clinical Hospital Centre Split, Division of Endocrinology, Diabetes and Metabolic Disease in Split, Šoltanska 1, School of Medicine Split, 21000 Split, Croatia.
出版信息
Diabetes Res Clin Pract. 2020 May;163:108163. doi: 10.1016/j.diabres.2020.108163. Epub 2020 Apr 23.
Abstract
摘要
相似文献
1
Letter to the editor in response to the article "COVID-19 and diabetes: Can DPP4 inhibition play a role?".致编辑的信：回应文章《2019冠状病毒病与糖尿病：二肽基肽酶4抑制能否发挥作用？》
Diabetes Res Clin Pract. 2020 May;163:108163. doi: 10.1016/j.diabres.2020.108163. Epub 2020 Apr 23.
2
Response to COVID-19 and diabetes: Can DPP4 inhibition play a role? - GLP-1 might play one too.对2019冠状病毒病（COVID-19）的反应与糖尿病：二肽基肽酶4（DPP4）抑制能否发挥作用？-胰高血糖素样肽1（GLP-1）可能也起作用。
Diabetes Res Clin Pract. 2020 Jun;164:108160. doi: 10.1016/j.diabres.2020.108160. Epub 2020 Apr 22.
3
COVID-19 and diabetes: Is this association driven by the DPP4 receptor? Potential clinical and therapeutic implications.2019冠状病毒病与糖尿病：这种关联是由二肽基肽酶4受体驱动的吗？潜在的临床和治疗意义。
Diabetes Res Clin Pract. 2020 May;163:108165. doi: 10.1016/j.diabres.2020.108165. Epub 2020 Apr 23.
4
COVID-19 and diabetes: Can DPP4 inhibition play a role?2019冠状病毒病与糖尿病：二肽基肽酶4抑制作用能否发挥作用？
Diabetes Res Clin Pract. 2020 Apr;162:108125. doi: 10.1016/j.diabres.2020.108125. Epub 2020 Mar 26.
5
COVID-19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity?新型冠状病毒肺炎（COVID-19）及其合并症：二肽基肽酶 4（DPP4）在疾病严重程度中的作用？
J Diabetes. 2020 Sep;12(9):649-658. doi: 10.1111/1753-0407.13052. Epub 2020 May 27.
6
Letter to the Editor: COVID-19 in patients with diabetes: Risk factors that increase morbidity.致编辑的信：糖尿病患者中的 COVID-19：增加发病率的风险因素。
Metabolism. 2020 Jul;108:154224. doi: 10.1016/j.metabol.2020.154224. Epub 2020 Apr 7.
7
Reply to the letter of Singh and Singh in response to the article: "Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis" (Kumar et al.).对辛格和辛格针对文章《糖尿病与2019冠状病毒病的死亡率及严重程度相关吗？一项荟萃分析》（库马尔等人著）所写信件的回复
Diabetes Metab Syndr. 2020 Sep-Oct;14(5):1147-1148. doi: 10.1016/j.dsx.2020.07.002. Epub 2020 Jul 8.
8
Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19.二肽基肽酶-4（DPP4）抑制剂在 COVID-19 中的作用。
Acta Diabetol. 2020 Jul;57(7):779-783. doi: 10.1007/s00592-020-01539-z. Epub 2020 Jun 6.
9
Letter to the editor in response to article: "Clinical considerations for patients with diabetes in times of COVID-19 epidemic (Gupta et al.).致编辑的信：对文章《2019冠状病毒病流行期间糖尿病患者的临床考量（古普塔等人）》的回应
Diabetes Metab Syndr. 2020 Jul-Aug;14(4):363. doi: 10.1016/j.dsx.2020.04.022. Epub 2020 Apr 18.
10
Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications.冠状病毒感染与 2 型糖尿病：具有治疗意义的共同途径。
Endocr Rev. 2020 Jun 1;41(3). doi: 10.1210/endrev/bnaa011.
引用本文的文献
1
Developmental Impacts of Epigenetics and Metabolism in COVID-19.表观遗传学与新陈代谢在新冠病毒病中的发育影响
J Dev Biol. 2024 Feb 9;12(1):9. doi: 10.3390/jdb12010009.
2
VEGFR and DPP-IV as Markers of Severe COVID-19 and Predictors of ICU Admission.VEGFR 和 DPP-IV 作为严重 COVID-19 的标志物和 ICU 收治的预测因子。
Int J Mol Sci. 2023 Nov 30;24(23):17003. doi: 10.3390/ijms242317003.
3
Efficacy and Safety of Sitagliptin in the Treatment of COVID-19.西他列汀治疗 COVID-19 的疗效和安全性。
J Pharm Pract. 2023 Aug;36(4):980-987. doi: 10.1177/08971900221102119. Epub 2022 May 17.
4
Interrelationship between 2019-nCov receptor DPP4 and diabetes mellitus targets based on protein interaction network.基于蛋白质相互作用网络的 2019-nCov 受体 DPP4 与糖尿病靶点的相互关系。
Sci Rep. 2022 Jan 7;12(1):188. doi: 10.1038/s41598-021-03912-6.
5
Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.鉴定 FDA 批准的针对 SARS-CoV-2 RNA 依赖性 RNA 聚合酶（RdRp）和 3-糜蛋白酶样蛋白酶（3CLpro）的药物，药物再利用方法。
Biomed Pharmacother. 2021 Jun;138:111544. doi: 10.1016/j.biopha.2021.111544. Epub 2021 Mar 31.
6
Is diabetes mellitus a wrongdoer to COVID-19 severity?糖尿病是否是 COVID-19 严重程度的罪魁祸首？
Diabetes Res Clin Pract. 2021 Aug;178:108936. doi: 10.1016/j.diabres.2021.108936. Epub 2021 Jul 1.
7
New thoughts on the diagnosis and treatment of patients with diabetes mellitus in relation to coronavirus disease.关于2019冠状病毒病相关糖尿病患者诊断和治疗的新思考
World J Diabetes. 2020 Nov 15;11(11):481-488. doi: 10.4239/wjd.v11.i11.481.
8
DPP-4 Inhibitors in the Prevention/Treatment of Pulmonary Fibrosis, Heart and Kidney Injury Caused by COVID-19-A Therapeutic Approach of Choice in Type 2 Diabetic Patients?二肽基肽酶-4抑制剂在预防/治疗新型冠状病毒肺炎所致肺纤维化、心脏和肾脏损伤中的应用——2型糖尿病患者的首选治疗方法？
Front Pharmacol. 2020 Aug 5;11:1185. doi: 10.3389/fphar.2020.01185. eCollection 2020.
9
Clinical Management of Diabetes Mellitus in the Era of COVID-19: Practical Issues, Peculiarities and Concerns.2019冠状病毒病时代糖尿病的临床管理：实际问题、特点与关切
J Clin Med. 2020 Jul 18;9(7):2288. doi: 10.3390/jcm9072288.
本文引用的文献
1
COVID-19 and diabetes: Can DPP4 inhibition play a role?2019冠状病毒病与糖尿病：二肽基肽酶4抑制作用能否发挥作用？
Diabetes Res Clin Pract. 2020 Apr;162:108125. doi: 10.1016/j.diabres.2020.108125. Epub 2020 Mar 26.
2
DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials.二肽基肽酶-4抑制剂与感染风险：一项随机对照试验的荟萃分析
Diabetes Metab Res Rev. 2016 May;32(4):391-404. doi: 10.1002/dmrr.2723. Epub 2015 Nov 2.
3
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC.二肽基肽酶 4 是新兴的人类冠状病毒-EMC 的功能性受体。
Nature. 2013 Mar 14;495(7440):251-4. doi: 10.1038/nature12005.
4
Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase.使用二肽基肽酶-4 抑制剂与感染报告：世界卫生组织国际药物监测计划数据库的一项比例失调分析。
Diabetes Care. 2011 Feb;34(2):369-74. doi: 10.2337/dc10-1771.
5
Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes.沙格列汀单药治疗对初治2型糖尿病患者的疗效。
Curr Med Res Opin. 2009 Oct;25(10):2401-11. doi: 10.1185/03007990903178735.
6
Dual inhibition of dipeptidyl peptidase IV and aminopeptidase N suppresses inflammatory immune responses.二肽基肽酶IV和氨肽酶N的双重抑制可抑制炎症免疫反应。
Ann N Y Acad Sci. 2007 Sep;1110:402-9. doi: 10.1196/annals.1423.042.
7
Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.二肽基肽酶IV抑制用于2型糖尿病治疗：对二肽基肽酶8和9选择性的潜在重要性
Diabetes. 2005 Oct;54(10):2988-94. doi: 10.2337/diabetes.54.10.2988.
Zotero 插件